Signatera™ exceeds 100 peer-reviewed publications, further validating our MRD leadership

Signatera™ exceeds 100 peer-reviewed publications, further validating our MRD leadership

Oncology

Natera is committed to oncology patients by optimizing therapy decisions from diagnosis to survivorship with actionable answers:

Tumor-informed, molecular residual disease (MRD) assessment and treatment response monitoring
Comprehensive genomic profiling to identify clinically relevant DNA & RNA biomarkers and can be run on the same sample as the MRD assay
Hereditary cancer testing includes commonly screened-for genes associated with 12+ types of cancer

Natera Oncology Portfolio

Watch now to learn more about Natera’s oncology suite of products.

Our Tests

Signatera™ - is cancer lurking?

Use Signatera™ ctDNA testing after surgery to evaluate the need for adjuvant chemotherapy and avoid unnecessary treatment.
Use Signatera™ to detect recurrence earlier while it may still be resectable, and reduce false positives.
Use Signatera™ during immunotherapy treatment to help evaluate treatment response.

Learn more

Altera™ – are there more treatment options?

Use Altera™ tumor genomic profiling to find more treatment options for cancer based on the tumor’s somatic profile.
Use Altera™ to discover potential clinical trials for patients with somatic mutations.
Order Altera™ with Signatera™ to get both tests from just one tissue.

Learn more

Latitude™ - tfMRD testing

A tissue-free, blood-based, residual disease test (MRD) that delivers fast and reliable results without the need for tumor tissue.

Learn more

Empower™ – can we target a germline mutation in treatment?

Use Empower™ to uncover germline (hereditary) mutations fast with our STAT testing option.
Use Empower™ to understand why cancer might be common in the family.

Learn more